Si Chuan Venture Capital
VC Fund
Chengdu, China
Si Chuan Venture Capital is a fund management and investment firm.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 28%
Last updated:
For AI agents: llms.txt
Industries Si Chuan Venture Capital invests in
BiotechnologyManufacturingMedicalPharmaceuticalArtificial Intelligence
Stages Si Chuan Venture Capital invests in
Series ASeries BVenture - Series UnknownSeedAngel
Countries Si Chuan Venture Capital invests in
ChinaHong KongUnited States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Yu Yan
|
|||
|
Zhang Fan
|
|||
Investment Focus
Industry
- Biotechnology 7 (39%)
- Manufacturing 4 (22%)
- Medical 3 (17%)
- Pharmaceutical 3 (17%)
- Artificial Intelligence 3 (17%)
Stage
- Series A 8 (44%)
- Series B 3 (17%)
- Venture - Series Unknown 2 (11%)
- Seed 1 (6%)
- Angel 1 (6%)
Country
- China 14 (78%)
- Hong Kong 1 (6%)
- United States 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Yu Yan
General manager
|
General manager | Total investments: 2 | Find email | |
|
Zhang Fan
Investment Director
|
Investment Director | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SeaArt
|
SeaArt is an AI creativity platform that provides tools for generating and editing images, videos, audio, and interactive AI character chats. The service includes text-to-image art generation, text-to-video and image-to-video creation, and an AI chatbot assistant with customizable characters. SeaArt also offers AI audio synthesis with multiplevoices, workflow control through ComfyUI, model training and hosting for Stable Diffusion based models, and swift AI tools for upscaling and filtering media. A built-in community enables sharing, remixing, challenges, and creator incentive programs for monetizing AI-generated works. | $14.7M / Series B / Jul 13, 2026 | |
|
Hailong Aerospace
|
Hailong Aerospace is a technological business that specializes in system solutions and high-precision attitude control components for commercial satellites. Hailong Aerospace specializes in high-precision satellite attitude control systems, specifically the "steering wheel" and "stabilizer" of commercial aircraft. | Angel / Jul 09, 2026 | |
Beixcell
|
Beixcell develops off-the-shelf cell therapies for patients with many degenerative diseases through universal iPSCs-derived cell products. | Series A / May 06, 2026 | |
New Radiomedicine Technology
|
Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $145.4M / Series E / Apr 03, 2026 | |
RootPath
|
RootPath is a Cambridge-based biotechnology company developing a powerful personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. Their next generation technologies allow us to precisely monitor, modulate and steer the immune system for a revolution in the diagnosis and treatment of cancer. | $1.4M / Venture - Series Unknown / Apr 24, 2025 | |
Geneus
|
Geneus is a developer of gene sequencers and reagents. | $13.7M / Series B / Mar 03, 2025 | |
Gene Vector
|
Chengdu Genevector Biotechnology Co., Ltd. (Genevector, Genevector) is a biotechnology company engaged in the research and development of new drugs for adeno-associated virus (AAV) gene therapy. The company is committed to the development of new AAV gene therapy drugs for ophthalmic diseases, neuromuscular diseases, genetic and metabolic diseases,etc. | Jan 03, 2025 | |
|
New Radiomedicine Technology
|
Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $41.7M / Series C / Mar 14, 2024 | |
Zenitar
|
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia. | Series B / Nov 24, 2023 | |
Gachun Biotech
|
Gachun Biotech is a pharmaceutical intermediates industrialization platform that focuses on APIs, or pharmaceutical intermediates. | $14.1M / Series A / Nov 23, 2023 | |
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Health Care Investors
43,014 investors
Artificial intelligence Investors
40,702 investors
Climate Investors
40,325 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
SaaS VC Funds
61,208 investors
FAQ
What does Si Chuan Venture Capital invest in?
Si Chuan Venture Capital invests primarily in Biotechnology, Manufacturing and Medical startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Si Chuan Venture Capital?
Public channels for Si Chuan Venture Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Si Chuan Venture Capital?
The team at Si Chuan Venture Capital includes Yu Yan (General manager) and Zhang Fan (Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
